Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Lowered by Wall Street Zen

Enliven Therapeutics (NASDAQ:ELVN) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Enliven Therapeutics Stock Up 0.2%

Shares of ELVN stock opened at $29.69 on Friday. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of -16.14 and a beta of 0.34. The stock has a fifty day moving average of $24.06 and a 200 day moving average of $21.52. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $30.22.

Insider Buying and Selling

In other Enliven Therapeutics news, COO Anish Patel sold 48,300 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.99, for a total value of $1,351,917.00. Following the completion of the transaction, the chief operating officer owned 215,011 shares in the company, valued at approximately $6,018,157.89. This represents a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard A. Heyman sold 1,230 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the sale, the director owned 22,647 shares in the company, valued at approximately $592,898.46. This trade represents a 5.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 233,843 shares of company stock valued at $6,145,489 over the last ninety days. Company insiders own 25.90% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Enliven Therapeutics during the fourth quarter valued at $83,000. Quantbot Technologies LP boosted its holdings in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after acquiring an additional 1,434 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Enliven Therapeutics in the fourth quarter worth $95,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.